Безопасность и качество пищевых продуктов
| share
 

Online Edition: "Residues of some veterinary drugs in foods and animals"

Online help   Terminology

This database contains the most recent information on maximum residue levels for veterinary drugs as recommended by JECFA. All monographs published in the FAO Food and Nutrition Papers 41 can be accessed in an electronic format. These monographs are available only in English although some parts of the database, the query page as well as the background information are provided in English, French, Spanish, Arabic and Chinese.

Veterinary Drug Avilamycin
Functional class Antimicrobial agent
Latest evaluation 2008
JECFA meeting 70
ADI 0-2 mg/kg bw
ADI status Full
Residue monographs  
Marker residue Dichloroisoeverninic acid (DIA)
Maximum residue limits
(MRL) recommended
ChickenFat/Skin200 µg/kgF
ChickenKidney200 µg/kgF
ChickenLiver300 µg/kgF
ChickenMuscle200 µg/kgF
PigFat/Skin200 µg/kgF
PigKidney200 µg/kgF
PigLiver300 µg/kgF
PigMuscle200 µg/kgF
RabbitFat/Skin200 µg/kgF
RabbitKidney200 µg/kgF
RabbitLiver300 µg/kgF
RabbitMuscle200 µg/kgF
TurkeyFat/Skin200 µg/kgF
TurkeyKidney200 µg/kgF
TurkeyLiver300 µg/kgF
TurkeyMuscle200 µg/kgF
Other remarks
Summary of the evaluation The ADI of 0-2 mg/kg bodyweight (0-120 mg per day for a 60 kg person) was established on the basis of a NOAEL of 150 mg/kg avilamycin activity/kg bodyweight and day and a safety factor of 100 and rounding to one significant figure.
Residue concentrations of the marker residue were not quantifiable or detected in muscle, skin/fat and kidney in pigs and chickens at a withdrawal time of 0 h or greater. Low residue concentrations were present in liver of all species studied in the first hours post-treatment, but were not quantifiable or detected after 24 h withdrawal.
The Estimated Daily Intake (EDI) was not determined because of insufficient quantifiable data points with which to calculate the median values of residues (low quantities of residues or absence of quantifiable residues). Using the model diet and the ratio of avilamycin equivalents to DIA, the recommended MRLs would result in a daily intake of 5.3 mg of avilamycin, approximately 4% of the upper bound of the ADI.